Abstract
Objectives:The objectives were to assess if a single intramuscular (IM) injection of the GnRH agonist triptorelin, as pamoate Sustained Release (RS) 11.25 mg, was able to induce pharmacological castration and to maintain the plasma testosterone levels in the castrate range (< 1.735 nmol/l) up to 3 months in prostatic carcinoma. Methods:Two different formulations of triptorelin pamoate 11.25 mg were assessed in 2 groups of 10 patients suffering from prostatic carcinoma. Each patient received one IM injection of triptorelin pamoate SR 11.25 mg. Triptorelin and testosterone levels were measured over 3 months. Pain, micturition difficulties, performance status, local and general tolerance, and the occurrence of adverse events were evaluated.Results: Both formulations were able to induce castration levels (< 1.735 nmol/l) of testosterone within 3 to 4 weekspost-injection, and to maintain levels below1.735 nmol/l till the end of 3rd month. The bioavailability of one formulation(DLGSD-3-95-21) tended to be greater.This may explain the quickeronset of castration and the slight better maintenance of low testosterone levels during the 3rd month observed with this formulation. In terms of clinical end-points, the local tolerance of both formulations was excellent. No serious adverse events were recorded except transient hot flushes in 2 cases and slight bone pain in one.Conclusion: Triptorelin pamoate 11.25 mg given in microgranules is a 3-month sustained-release administration form which appears to be safe and effective in advanced prostatic carcinoma. Based on the findings of this study, the formulation with greater bioavailability (DLGSD-3-95-21) was selected as formulation of choice to be used for clinical treatments and further clinical investigation.
Similar content being viewed by others
References
Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991; 324: 93–103.
Schally AV, Redding TW, Comaru-Schally AM. Inhibition of prostate tumors by agonistic and antagonistic analogs of LHRH. Prostate 1983; 4: 545–552.
De Sy, De Meyer JM, Casselman J, De Smet R, Renders G, Schelfhout W, De Wilde P. A comparative study of a long acting luteinizing hormone releasing hormone agonist (decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Acta Urol Belg 1986; 54: 221–229
Parmar H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH micropsules in advanced prostatic carcinoma. Lancet 1985; 2: 1201–1205.
Roger M, Duchier J, Lahlou N, Nahoul K, Schally AV. Treatment of prostatic carcinoma with D-Trp-6-LH-RH: plasma hormone levels after daily subcutaneous injections and periodic administration of delayed-release preparations. The Prostate 1985; 7: 271–282.
Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994; 331: 996–1004.
Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer 1993; 71: 1089–1097.
Gittes RF. Carcinoma of the prostate. N Engl JMed 1991; 324: 236–245.
Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, François R, Garandeau P, Lahlou N, Morel Y, Schally AV. Long term treatment of male and female precocious puberty by periodic administration of a longacting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Met 1986; 62: 670–677.
Scott J, Huckisson EC. Graphic representation of pain. Pain 1976; 2: 175–184.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Minkov, N.K., Zozikov, B.I., Yaneva, Z. et al. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. Int Urol Nephrol 33, 379–383 (2001). https://doi.org/10.1023/A:1015274031704
Issue Date:
DOI: https://doi.org/10.1023/A:1015274031704